Low-dose and long-term azithromycin significantly decreases Staphylococcus aureus in the microbiome of refractory CRS patients.

Axel Eluid RenteriaAnastasios ManiakasLeandra Endam MfunaMarc-Henri AsmarEmmanuel GonzalezMartin Desrosiers

Published in: International forum of allergy & rhinology (2020)

A 4-month course of 250 mg of azithromycin 3 times weekly in patients with refractory CRS significantly decreases S. aureus abundance in the sinonasal microbiome. Considering the pathogenic role of S. aureus in the refractory CRS population, azithromycin may constitute an additional therapeutic option to help control this disease.

Keyphrases

low dose
staphylococcus aureus
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
high dose
escherichia coli
cystic fibrosis
patient reported outcomes
microbial community
biofilm formation
methicillin resistant staphylococcus aureus
candida albicans